B-LONG boost for Biogen Idec & Sobi in haemophilia
This article was originally published in Scrip
Executive Summary
Swedish Orphan Biovitrum (Sobi) saw its share price rocket by up to 48% (€38.40) in the afternoon of 26 September after its partner Biogen Idec (+2.6% to $157 on opening) released positive top-line data for their long-lasting recombinant Factor IX fusion protein product (rFIXFc) in haemophilia B.